Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.66 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.66 |
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.66 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 3/20 | 0.48 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.46 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP7 | P09237 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28445682 | 0.94 | CA2 (0.55) | CA1CA2CA12CA9MAOA | |
| Silver SCHEMBL4326545 | 0.89 | CA2 (0.55) | CA1CA2CA12CA9MAOA | |
| SCHEMBL3171668 | 0.82 | CA12 (0.52) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL5846996 | 0.82 | CA12 (0.52) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL5078517 | 0.81 | CA1 (0.56) | CA1CA2CA12CA9MAOA | |
| SCHEMBL309411 | 0.79 | CA1 (0.66) | CA1CA2CA12CA9MAOA | |
| SCHEMBL4190362 | 0.79 | PTGS2 (0.72) | CA1CA2CA12CA9MAOA | |
| SCHEMBL4377093 | 0.79 | CA12 (0.66) | CA1CA2CA12CA9MAOA | |
| SCHEMBL6027018 | 0.78 | CA1 (0.63) | CA1CA2CA12CA9MAOA | |
| Hydrochloric Acid SCHEMBL8880917 | 0.78 | CA1 (0.63) | CA1CA2CA12CA9MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1696915-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | Pfizer, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AGOURON PHARMACEUTICALS, INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005060963-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | PFIZER INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B11, HSD11B2 | CA1 357/4885CA2 997/4885CA12 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.